ReviewPharmacological research2009
Endocannabinoids and cardiac contractile function: pathophysiological implications.
Review in Pharmacological research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- Exacerbated cardiac dysfunction from combined alcohol binge and synthetic cannabinoid use.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- Differential Regulation of MMPs, Apoptosis and Cell Proliferation by the Cannabinoid Receptors CB1 and CB2 in Vascular Smooth Muscle Cells and Cardiac Myocytes.Biomedicines · 2022Article
- Pharmacognosy and Effects of Cannabinoids in the Vascular System.ACS pharmacology & translational science · 2022Review
- Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis.GeroScience · 2022Article
- Cardiac-specific microRNA-125b deficiency induces perinatal death and cardiac hypertrophy.Scientific reports · 2021Article
- Review
- Activity-based protein profiling of the human failing ischemic heart reveals alterations in hydrolase activities involving the endocannabinoid system.Pharmacological research · 2020Article
- Occurrence of Takotsubo Cardiomyopathy after Synthetic Cannabinoid Consumption.Addiction & health · 2019Article
- Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.Antioxidants & redox signaling · 2018Review
- Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.Nature reviews. Cardiology · 2018Review
- Microbes, Immunity, and Behavior: Psychoneuroimmunology Meets the Microbiome.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Review
- Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes.British journal of pharmacology · 2014Article
- Cannabis use: signal of increasing risk of serious cardiovascular disorders.Journal of the American Heart Association · 2014Article
- Modulating the endocannabinoid system in human health and disease--successes and failures.The FEBS journal · 2013Review
- Is the cardiovascular system a therapeutic target for cannabidiol?British journal of clinical pharmacology · 2013Review
- Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?British journal of pharmacology · 2012Review
- Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.Free radical biology & medicine · 2011Review
- Is lipid signaling through cannabinoid 2 receptors part of a protective system?Progress in lipid research · 2011Review
- Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury.Free radical biology & medicine · 2011Article
- CB(1) cannabinoid receptors and their associated proteins.Current medicinal chemistry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Endocannabinoids are part of a bioactive lipid signaling system, not only in the central nervous system but also in various peripheral organs. Accumulating evidence implicates dysregulation of the endocannabinoid system (ECS) in the pathogenesis of various cardiovascular diseases, including hypertension, atherosclerosis, myocardial infarction, hemorrhagic or septic shock, heart failure and cardiovascular complications of liver cirrhosis. Even though the benefit of chronic cannabinoid 1 (CB1) receptor blockade with the currently available compounds may not outweigh the risks in chronic conditions such as obesity, modulation of the ECS may hold great therapeutic promise in various cardiovascular conditions/disorders. In this review we will discuss recent advances in understanding the role of CB1 receptors and endocannabinoids in the regulation of cardiac function in cirrhotic cardiomyopathy and in doxorubicin-induced heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.